These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31796507)

  • 1. Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling.
    Nakai S; Tamiya H; Imura Y; Nakai T; Yasuda N; Wakamatsu T; Tanaka T; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Yoshikawa H; Naka N
    Mol Cancer Ther; 2020 Mar; 19(3):742-754. PubMed ID: 31796507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
    Kawano S; Asano M; Adachi Y; Matsui J
    Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin induces tumor vascular remodeling through intussusceptive angiogenesis in a sarcoma xenograft model.
    Taguchi E; Horiuchi K; Senoo A; Susa M; Inoue M; Ishizaka T; Rikitake H; Matsuhashi Y; Chiba K
    Biochem Biophys Res Commun; 2021 Sep; 570():89-95. PubMed ID: 34274851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The melanocyte inducing factor MITF is stably expressed in cell lines from human clear cell sarcoma.
    Li KK; Goodall J; Goding CR; Liao SK; Wang CH; Lin YC; Hiraga H; Nojima T; Nagashima K; Schaefer KL; Lee KA
    Br J Cancer; 2003 Sep; 89(6):1072-8. PubMed ID: 12966428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.
    Nakai T; Imura Y; Tamiya H; Yamada S; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
    Cancer Med; 2017 Sep; 6(9):2121-2130. PubMed ID: 28745431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.
    Davis IJ; Kim JJ; Ozsolak F; Widlund HR; Rozenblatt-Rosen O; Granter SR; Du J; Fletcher JA; Denny CT; Lessnick SL; Linehan WM; Kung AL; Fisher DE
    Cancer Cell; 2006 Jun; 9(6):473-84. PubMed ID: 16766266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
    Funahashi Y; Okamoto K; Adachi Y; Semba T; Uesugi M; Ozawa Y; Tohyama O; Uehara T; Kimura T; Watanabe H; Asano M; Kawano S; Tizon X; McCracken PJ; Matsui J; Aoshima K; Nomoto K; Oda Y
    Cancer Sci; 2014 Oct; 105(10):1334-42. PubMed ID: 25060424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
    Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Takahashi K; Fujita H; Shibutani M; Amano R; Takashima T; Tomita S; Hirakawa K; Ohira M
    BMC Cancer; 2020 Dec; 20(1):1215. PubMed ID: 33302911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eribulin shows high concentration and long retention in xenograft tumor tissues.
    Sugawara M; Condon K; Liang E; DesJardins C; Schuck E; Kusano K; Lai WG
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):377-384. PubMed ID: 28664226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models.
    Ito K; Hamamichi S; Abe T; Akagi T; Shirota H; Kawano S; Asano M; Asano O; Yokoi A; Matsui J; Umeda IO; Fujii H
    Cancer Sci; 2017 Nov; 108(11):2273-2280. PubMed ID: 28869796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.
    De Vita A; Miserocchi G; Recine F; Mercatali L; Pieri F; Medri L; Bongiovanni A; Cavaliere D; Liverani C; Spadazzi C; Amadori D; Ibrahim T
    Molecules; 2016 Dec; 21(12):. PubMed ID: 27918490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clear cell tumor with melanocytic differentiation and MITF-CREM translocation: a novel entity similar to clear cell sarcoma.
    de la Fouchardiere A; Pissaloux D; Tirode F; Hanna J
    Virchows Arch; 2021 Oct; 479(4):841-846. PubMed ID: 33462743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells.
    Hayasaka N; Takada K; Nakamura H; Arihara Y; Kawano Y; Osuga T; Murase K; Kikuchi S; Iyama S; Emori M; Sugita S; Hasegawa T; Takasawa A; Miyanishi K; Kobune M; Kato J
    Sci Rep; 2019 Apr; 9(1):5759. PubMed ID: 30962488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.
    López-Álvarez M; González-Aguilera C; Moura DS; Sánchez-Bustos P; Mondaza-Hernández JL; Martín-Ruiz M; Renshaw M; Ramos R; Castilla C; Blanco-Alcaina E; Hindi N; Martín-Broto J
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MITF::CREM-rearranged tumor: a novel group of cutaneous tumors with melanocytic differentiation.
    Kalmykova A; Mosaieby E; Kacerovská D; Baranovska-Andrigo V; Martínek P; Smahová S; Michal M; Michal M
    Virchows Arch; 2023 Oct; 483(4):569-575. PubMed ID: 37550584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases.
    Antonescu CR; Tschernyavsky SJ; Woodruff JM; Jungbluth AA; Brennan MF; Ladanyi M
    J Mol Diagn; 2002 Feb; 4(1):44-52. PubMed ID: 11826187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
    J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma.
    Nakano T; Fujimoto K; Tomiyama A; Takahashi M; Achiha T; Arita H; Kawauchi D; Yasukawa M; Masutomi K; Kondo A; Narita Y; Maehara T; Ichimura K
    Cancer Sci; 2022 Feb; 113(2):697-708. PubMed ID: 34839570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines.
    Tanaka S; Ishii T; Sato F; Toi M; Itou J
    Biochem Biophys Res Commun; 2020 May; 526(1):154-157. PubMed ID: 32201082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.
    Yokoyama S; Feige E; Poling LL; Levy C; Widlund HR; Khaled M; Kung AL; Fisher DE
    Pigment Cell Melanoma Res; 2008 Aug; 21(4):457-63. PubMed ID: 18627530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.